Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 16 to 30 of 129 results for epilepsy

  1. The contractor establishes and maintains a register of patients aged 18 or over receiving drug treatment for epilepsy.

    patients aged 18 or over receiving drug treatment for epilepsy. Subject(s): Epilepsy Date of publication: 21 August 2023

    General practice indicator suitable for use in the QOF
    Published
    18 August 2023

  2. Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over [ID1651]

    In development [GID-TA10653] Expected publication date: 22 May 2024

    Technology appraisal guidance
    In development

  3. Unplanned hospitalisation for asthma, diabetes and epilepsy in under 19s

    Unplanned hospitalisation for asthma, diabetes and epilepsy in under 19s Subject(s): Outpatient and community care

    National library quality indicator
    Published
    10 February 2022

  4. The percentage of patients aged 18 or over on drug treatment for epilepsy who have been seizure free for the last 12 months recorded in the preceding 12 months

    treatment for epilepsy who have been seizure free for the last 12 months recorded in the preceding 12 months Subject(s):...

    General practice indicator suitable for use in the QOF
    Published
    21 April 2022

  5. Epilepsy syndromes: What are the initial and add-on AEDs of choice in the treatment of the epilepsy syndromes with onset in childhood, for example, myoclonic-astatic epilepsy and Dravet syndrome?

    CG137/2 Question Epilepsy syndromes: What are the initial and add-on AEDs of choice in the treatment of the epilepsy...

    Research recommendation
    Published
    13 August 2021

  6. Cannabidiol for treating seizures caused by tuberous sclerosis complex (TA873)

    Evidence-based recommendations on cannabidiol (Epidyolex) for treating seizures caused by tuberous sclerosis complex.

    Technology appraisal guidance
    Published
    1 March 2023
    View recommendations

    Sections for TA873

  7. The percentage of women with epilepsy who are aged 18 or over, but under 45, who are taking antiseizure medications and have a record of being given information and advice in the previous 12 months about pregnancy or conception, or contraception tailored to their pregnancy and contraceptive intentions.

    NICE indicators. NM71 epilepsy guidance.

    General practice indicator suitable for use outside of the QOF
    Published
    4 May 2022

  8. Risk prediction tool for all-cause epilepsy-related death: Development of a risk prediction tool to detect all-cause mortality including sudden unexpected death in epilepsy (SUDEP) in people with epilepsy or those who have had a single seizure, and an external validation of a risk prediction tool to detect the probability of epilepsy-related death.

    all-cause epilepsy-related death: Development of a risk prediction tool to detect all-cause mortality including sudden unexpected death...

    Research recommendation
    Published
    11 May 2022

  9. Transition from children's to adults' services

    NICE's impact on transition from children’s to adults’ services

  10. Fenfluramine for treating seizures associated with Dravet syndrome (TA808)

    Evidence-based recommendations on fenfluramine (Fintepla) for treating seizures associated with Dravet syndrome in people aged 2 and older.

    Technology appraisal guidance
    Published
    8 July 2022
    View recommendations

    Sections for TA808

  11. Autism spectrum disorder in under 19s: support and management (CG170)

    This guideline covers children and young people with autism spectrum disorder (across the full range of intellectual ability) from birth until their 19th birthday. It covers the different ways that health and social care professionals can provide support, treatment and help for children and young people with autism, and their families and carers, from the early years through to their transition into young adult life.

    Clinical guideline
    Last updated
    14 June 2021
    View recommendations

    Sections for CG170

  12. Complex epilepsy syndromes: What antiseizure therapies (alternative or add-on) are effective in the treatment of complex epilepsy syndromes (that is, Dravet syndrome, Lennox–Gastaut syndrome, infantile spams syndrome and epilepsy with myoclonic-atonic seizures [Doose syndrome]) when first-line therapy is unsuccessful or not tolerated?

    Question Complex epilepsy syndromes: What antiseizure therapies (alternative or add-on) are effective in the treatment of complex...

    Research recommendation
    Published
    11 May 2022

  13. Transient loss of consciousness ('blackouts') in over 16s (QS71)

    This quality standard covers assessing, diagnosing and referring people (aged 16 and over) who have had a transient loss of consciousness (often called a blackout). It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    2 October 2014
    View quality statements

    Sections for QS71

  14. Cannabidiol with clobazam for treating seizures associated with Dravet syndrome (TA614)

    Evidence-based recommendations on cannabidiol (Epidyolex) with clobazam for seizures associated with Dravet syndrome in people aged 2 years and older.

    Technology appraisal guidance
    Published
    18 December 2019
    View recommendations

    Sections for TA614

  15. Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over [ID3988]

    In development [GID-TA10948] Expected publication date: 26 June 2024

    Technology appraisal guidance
    In development